Technical Analysis for GWPH - GW Pharmaceuticals Plc

Grade Last Price % Change Price Change
grade F 113.95 4.19% 4.58
GWPH closed up 4.19 percent on Monday, August 10, 2020, on 1.96 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical GWPH trend table...

Date Alert Name Type % Chg
Jack-in-the-Box Bearish Bearish Swing Setup 0.00%
Crossed Above 200 DMA Bullish 0.00%
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Below Lower BB Weakness 0.00%
Fell Below 200 DMA Bearish 4.19%
Fell Below 50 DMA Bearish 4.19%
MACD Bearish Centerline Cross Bearish 4.19%
Expansion Breakdown Bearish Swing Setup 4.19%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

GW Pharmaceuticals plc, together with its subsidiaries, engages in the research, development, and commercialization of a range of cannabinoid prescription medicines. The company primarily offers Sativex, an oromucosal spray for the treatment of MS symptoms, cancer pain, and neuropathic pain. It also focuses on the Phase III clinical development program of Sativex for use in treatment of cancer pain. In addition, the company has two product candidates in Phase II trials in the field of diabetes and inflammation, as well as pre-clinical research programmes evaluating the use of selected cannabinoids for the treatment of glioma, epilepsy, and psychiatric illness. It has a strategic alliance with Otsuka Pharmaceutical Co. Ltd. The company operates in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Salisbury, the United Kingdom.
Health Cancer Pharmaceutical Industry Pain Drugs Treatment Of Cancer Diabetes Medication Inflammation Pharmaceuticals Policy Cannabis Epilepsy Glioma Cannabinoids Neuropathic Pain

Is GWPH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 158.255
52 Week Low 67.98
Average Volume 335,728
200-Day Moving Average 112.62
50-Day Moving Average 128.03
20-Day Moving Average 130.51
10-Day Moving Average 126.89
Average True Range 6.39
ADX 20.15
+DI 15.80
-DI 35.97
Chandelier Exit (Long, 3 ATRs ) 122.82
Chandelier Exit (Short, 3 ATRs ) 126.16
Upper Bollinger Band 145.60
Lower Bollinger Band 115.43
Percent B (%b) -0.05
BandWidth 23.12
MACD Line -1.72
MACD Signal Line 0.37
MACD Histogram -2.092
Fundamentals Value
Market Cap 2.89 Billion
Num Shares 25.4 Million
EPS -5.64
Price-to-Earnings (P/E) Ratio -20.20
Price-to-Sales 253.36
Price-to-Book 6.23
PEG Ratio 0.33
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 118.75
Resistance 3 (R3) 118.39 116.42 117.95
Resistance 2 (R2) 116.42 115.20 116.61 117.68
Resistance 1 (R1) 115.19 114.45 115.81 115.55 117.42
Pivot Point 113.22 113.22 113.53 113.41 113.22
Support 1 (S1) 111.99 112.00 112.61 112.35 110.48
Support 2 (S2) 110.02 111.25 110.21 110.22
Support 3 (S3) 108.79 110.02 109.95
Support 4 (S4) 109.15